<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04118530</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC35420</org_study_id>
    <nct_id>NCT04118530</nct_id>
  </id_info>
  <brief_title>Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant</brief_title>
  <acronym>ARCHER</acronym>
  <official_title>Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant Survivors: Reveal Linq Cancer Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand the following aims:&#xD;
&#xD;
        1. Aim 1: To evaluate the rate of recurrent Atrial Fibrillation (AF)/Atrial Flutter (AFL)&#xD;
           in hematopoietic stem call transplant (HCST) patients with incident AF/AFL identified&#xD;
           during the initial 30 days of the transplant&#xD;
&#xD;
        2. Aim 2: To evaluate incident episodes of 1) stroke/TIA; 2) other thromboembolic events&#xD;
           (not stroke/TIA); 3) Heart failure events; 4) Ischemic heart events&#xD;
&#xD;
        3. Aim 3: To evaluate overall implantation safety in this population&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose a registry study in hematopoietic stem cell transplant (HSCT) patients with&#xD;
      incident atrial fibrillation/atrial flutter (AF/AFL) during the initial 30 days of transplant&#xD;
      who will be implanted with the Medtronic Reveal Linq Implantable Cardiac Monitor (ICM) within&#xD;
      90 days of HSCT. We will evaluate the rate of recurrent AF/AFL as well as incident episodes&#xD;
      of major cardiovascular events and the safety of ICM implantation in this population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Recurrent AF/AFL episodes</measure>
    <time_frame>1 year</time_frame>
    <description>Any recurrent episodes of AF/AFL lasting ≥2 minutes identified in ICM monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incident Episodes of Interest</measure>
    <time_frame>1 year</time_frame>
    <description>Incident episodes of: stroke/TIA; other thromboembolic events (not stroke/TIA); Heart failure events; ischemic heart events. Overall device implantation safety.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hematopoietic Stem Cell Transplant</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplant (HSCT) Patients</arm_group_label>
    <description>- Patients with incidence of AF/AFL in the first 30 days of transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HSCT Patients</intervention_name>
    <description>Prospective, observational review of incidence of AF/AFL through Carelink remote monitoring and safety of implantation of device in this population of patients through review of standard of care follow up visits post HSCT implant</description>
    <arm_group_label>Hematopoietic Stem Cell Transplant (HSCT) Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with the diagnosis that requires them to undergo HSCT who develop incident&#xD;
        AF/AFL in the first 30 days of transplant.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18&#xD;
&#xD;
          2. CHADS-VASc ≥ 2&#xD;
&#xD;
          3. Recovery of platelets to &gt;50,000 within 90 days of incident atrial fibrillation (AF)&#xD;
             diagnosis&#xD;
&#xD;
          4. Discharge from the incident stem cell transplant (SCT) hospitalization&#xD;
&#xD;
          5. Normal sinus rhythm at the time of consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior history of atrial fibrillation (AF) or atrial flutter&#xD;
&#xD;
          2. CHADS-VASc &lt;2&#xD;
&#xD;
          3. Platelets &lt;50,000 after 90 days post transplantation&#xD;
&#xD;
          4. Continued SCT hospitalization at 90 days&#xD;
&#xD;
          5. Inability to receive anticoagulation&#xD;
&#xD;
          6. AF or other arrhythmia at the time of consent&#xD;
&#xD;
          7. Current use of a class IC or III antiarrhythmic medication&#xD;
&#xD;
          8. Inability to provide informed consent/significant cognitive impairment&#xD;
&#xD;
          9. Expected survival less than one year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Fradley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Fradley, MD</last_name>
    <phone>215-611-6799</phone>
    <email>michael.fradley@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Smith, BA, MA</last_name>
    <email>amanda.smith4@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Abramson Cancer Center at University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Fradley, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 5, 2019</study_first_submitted>
  <study_first_submitted_qc>October 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Hematopoietic Stem Cell Transplant</keyword>
  <keyword>Atrial Flutter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

